New Zealand's Malaghan Institute expands cancer Car-T cell therapy trial to 60 patients in phase 2.
New Zealand's Malaghan Institute is expanding its groundbreaking Car-T cell therapy trial for cancer, with 60 patients set to receive treatment in the trial's second phase over two years. The therapy involves modifying a patient's immune cells to recognise and kill cancer, and is a potential game-changer for certain cancers. The phase 2 clinical trial is set to confirm effectiveness and safety of the New Zealand-developed CAR T-cell therapy.
July 22, 2024
4 Articles